BillionToOne, Inc.
NASDAQ:BLLNMedical - Diagnostics & Research
+$0.84 today
- Market cap
- $4.37B
- Beta
- 0.90
- P/E (TTM)
- 182.6
- EPS (TTM)
- $0.55
Volume 1.44M
Average 0.59M
BLLN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
BillionToOne, Inc.NASDAQ: BLLN
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 190.3% from a year ago
Cash & equivalents stood at $548.63M at the end of Q2 FY2026, up 190.3% from a year earlier and up 2.1% from the prior quarter.
Context
- Cash & equivalents amounted to 75.2% of total assets at the end of Q2 FY2026, up 14.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +190.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 495.98M USD
- Year-over-year change
- +159.0%
- 2-year CAGR
- +125.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 495.98M | +159.0% |
| FY2024 | 2024-12-31 | 191.48M | +96.9% |
| FY2023 | 2023-12-31 | 97.27M | — |
Cash & Equivalents vs competitors
How BLLN compares with its peers on the latest reported figures
- BLLN's Jun 2026 cash & equivalents of $548.63M is the 3rd highest of the 9 companies compared; the peer median is $134.97M.
- Its year-over-year change of +190.3% is the highest of 9, against a peer median of +1.6%.
- Cash & equivalents amounts to 75.2% of total assets for BLLN, versus a peer median of 15.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.09B | +9.1% | +32.2% | 41.1% | |
| Sep 2026 | $1.03B | +77.0% | +38.7% | 54.5% | |
BLLNBillionToOne, Inc. | Jun 2026 | $548.63M | +190.3% | — | 75.2% |
| Jun 2026 | $299.52M | +36.5% | +33.0% | 20.2% | |
| Jun 2026 | $145.54M | -5.9% | -15.4% | 10.8% | |
| Mar 2026 | $124.4M | +35.5% | +38.0% | 18.5% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $60.32M | -18.6% | -8.6% | 12.5% |
| Jun 2026 | $55.65M | -56.3% | +1.1% | 2.0% | |
| Mar 2026 | $23.4M | -65.2% | -14.2% | 2.0% | |
| Peer median (excluding BLLN) | $134.97M | +1.6% | +16.6% | 15.5% | |
Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BillionToOne, Inc.
NASDAQ:BLLN
Intrinsic Alpha fair value
Locked
Current Price
$91.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.